Medical/Pharmaceuticals

World Thrombosis Day encourages public to "Move Against Thrombosis" to celebrate 10 years of raising awareness worldwide

CHAPEL HILL, N.C., Oct. 13, 2023 /PRNewswire/ -- Today is World Thrombosis Day, a global effort by the International Society on Thrombosis and Haemostasis  (ISTH) to spread awareness of the signs, symptoms and risk factors of thrombosis, commonly known as blood clots. World Thrombosis Day engages...

2023-10-13 15:00 735

GenScript ProBio Congratulates ABL Bio's IND Clearance of ABL103 Program from MFDS

SEOUL, South Korea, Oct. 13, 2023 /PRNewswire/ -- Recently, ABL Bio, a partner of GenScript ProBio, announced the Ministry of Food and Drug Safety (MFDS) cleared of its clinical trial application for innovative bispecific antibody program (B7H4x4-1BB) in solid tumor. GenScript ProBio warmly exten...

2023-10-13 09:00 2277

M42 Announces New Clinical LLM to Transform the Future of AI in Healthcare

ABU DHABI, UAE, Oct. 13, 2023 /PRNewswire/ -- M42, a global tech-enabled healthcare network, has unveiled an impactful advancement in healthcare technology with the launch of Med42, a new open-access Clinical Large Language Model (LLM). The 70 billion parameter, generative artificial intelligence...

2023-10-13 01:26 2261

Discovery Life Sciences Announces Major Strategic Expansions: New State-of-the-Art Facilities, Advanced Technologies, and Global Brand Enhancements

HUNTSVILLE, Ala., Oct. 12, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, has moved to its new global headquarters at the HudsonAlpha Institute of Biotechnology campus in Huntsville, Alabama. Alongside this relocation, the company's AllCells ce...

2023-10-12 22:00 2015

Emulate Earns Frost & Sullivan's 2023 Technology Innovation Leadership Award

Cutting-edge Organ-on-a-Chip Technology Enhances R&D Productivity and Improves Patient Safety SAN ANTONIO, Oct. 12, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the North American Organ-on-a-Chip industry and, based on its findings, recognizesEmulate with the 2023 Technology Innovat...

2023-10-12 20:00 1541

Metabolon Launches New Liver Fibrosis and Kidney Function Discovery Panels to Reveal Disease Mechanisms and Facilitate Research

Metabolon's newest panels help academic and commercial researchers reveal complex biological insights about liver fibrosis and kidney dysfunction MORRISVILLE, N.C., Oct. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of lif...

2023-10-12 19:57 1429

Scott's and 99Speedmart Join Forces to Launch Donation Campaign to Serve Underprivileged Children's Nutritional Needs

* One-month BUY1DONATE1 campaign to be rolled out nationwide, enabling anyone to take part in giving back * Donations of Scott's products to supplement the nutritional needs of 5,000 underprivileged children KUALA LUMPUR, Malaysia, Oct. 12, 2023 /PRNewswire/ -- Scott's, the market leader in t...

2023-10-12 18:56 2159

Neoss® Group receives EU Medical Device Regulation (MDR) certifications for implants and abutments

ZÜRICH, Oct. 12, 2023 /PRNewswire/ -- Neoss Group, a leading innovator in dental implant solutions, is proud to announce that it has received EU Medical Device Regulation (MDR) certification by its Notified Body, the BSI Group, the Netherlands B.V. for its implants and abutments. This certificati...

2023-10-12 18:34 1522

Prestigious World Congress of Neurology Returns In-Person to Convene World-Class Researchers in Montreal

MONTREAL, Oct. 12, 2023 /PRNewswire/ -- The World Federation of Neurology (WFN) and the Canadian Neurological Society (CNS) will host theXXVI World Congress of Neurology (WCN) in Montreal, Canada, from October 15 to 19, 2023. WCN is a major, biennial conference where world-class neurologists and ...

2023-10-12 18:00 1563

ALLORION THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 STUDY OF ARTS-021, A POTENTIAL BEST IN CLASS CDK2 INHIBITOR, FOR ADVANCED OR METASTATIC SOLID TUMORS

NATICK, Mass., Oct. 12, 2023 /PRNewswire/ -- Allorion Therapeutics (Allorion), a clinical-stage biotechnology company dedicated to the discovery and development of next-generation targeted drugs for cancer and autoimmune diseases, announced today the dosing of its first patient in the Phase 1/2 ...

2023-10-12 10:37 1623

Suvoda Introduces Advanced Drug Optimization For IRT to Improve Accuracy of Clinical Trial Drug Supply Management

Greater Control Over Drug Supply Management Helps Sponsors Reduce Costs and Carbon Footprint PHILADELPHIA, Oct. 12, 2023 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), an...

2023-10-12 09:00 1939

Gencurix Receives Australian Government Approval for Droplex POLE Mutation Test

SEOUL, South Korea, Oct. 12, 2023 /PRNewswire/ -- Gencurix , a cancer molecular diagnostics company, has obtained approval from the Australian Government (The Department of Health and Aged Care, Therapeutic Goods Administration) for its Droplex POLE Mutati...

2023-10-12 06:00 2022

KHB Becomes First Chinese Company to Obtain EU Class D IVDR Certification for Its Rapid Test HIV Colloidal Gold Diagnostic Kit

SHANGHAI, Oct. 11, 2023 /PRNewswire/ -- Shanghai Kehua Bio-engineering Co., Ltd ("KHB" or "the Company", Stock code: 002022.SZ),China's leading In Vitro Diagnostic (IVD) company has achieved a significant milestone by becoming the first Chinese company to obtain EU Clas...

2023-10-11 16:27 2534

Smith+Nephew opens new state-of-the-art surgical innovation and training centre in the heart of Munich

LONDON, Oct. 11, 2023 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company specialising in orthopaedics, advanced wound management and sports medicine, is pleased to announce the opening of the purpose-built Smith+Nephew Academy Munich, a new centre for surgica...

2023-10-11 14:00 3354

Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023

HANGZHOU and SHAOXING, China, Oct. 11, 2023  /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of Phase II study topline results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the European Academy of Der...

2023-10-11 08:10 2151

VISTA Eye Specialist Achieves International Recognition at European Congress

PETALING JAYA, Malaysia, Oct. 11, 2023 /PRNewswire/ -- Last September, VISTA Eye Specialist proudly marked its presence at the prestigious European Society of Cataract and Refractive Surgery (ESCRS) Symposium and Congress inVienna, Austria. This event, the second participation since the onset of ...

2023-10-11 08:00 2028

EADV Congress: Non-melanoma skin cancer killing more people than melanoma, new study finds

BERLIN, Oct. 11, 2023 /PRNewswire/ -- Non-melanoma skin cancer (NMSC) is causing a greater number of global deaths than melanoma, the more serious form of skin cancer, a new study presented today at the EADV Congress 2023 has found. Researchers also believe that NMSC is underreported and that the...

2023-10-11 06:01 1870

SAFETYscan47: A Valuable Component in Revolutionizing Chemical Risk Assessments for Global Health and Safety

SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Eurofins Discovery, an industry-leading provider of products and services for drug discovery research, today announced its SAFETYscan®47 platform as a New Approach Methodology (NAM), part of a standardized framework aiming to revolutionize chemical risk a...

2023-10-10 23:10 1955

Novel classification of allergic disorders published by the European Academy of Allergy and Clinical Immunology: SIAF

Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper published in 'Allergy' DAVOS, Switzerland, Oct. 10, 2023 /PRNewswire/ -- The revision of the current allergic disease nomenclature based on symptoms and organ dysfunction has been l...

2023-10-10 19:10 1402

Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer

-- STX-721 is characterized by high selectivity and a potentially best-in-class profile -- -- Scorpion's second program to enter clinical development this year -- -- One of two EGFR programs being developed with Pierre Fabre Laboratories --  BOSTON and CASTRES, France, Oct. 10, 2023 /PRNewswire/...

2023-10-10 18:00 1575
1 ... 78798081828384 ... 397

Week's Top Stories